Clinical Trials Logo

Human Papilloma Virus Infection clinical trials

View clinical trials related to Human Papilloma Virus Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05439083 Recruiting - Clinical trials for Human Papilloma Virus Infection

Immunogenicity of 9-valent HPV Vaccine

Start date: March 7, 2023
Phase: Phase 4
Study type: Interventional

Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately 90% of cervical and other HPV-related anogenital cancers, as well as 90% of genital warts. The risk of cancer is substantially increased among immunocompromised patients. Although studies have demonstrated seroprotection among children and adolescents, boys and girls, with the 9vHPV vaccine, the immunogenicity of this vaccine has been poorly explored in immunocompromised children and adolescents (including transplant patients, and those infected with human immunodeficiency virus (HIV)). Several factors, including the immunological consequences of vertically acquired infection, immunosuppressive therapies and age, could lead to an increased risk of infection in children and adolescents who are immunocompromised. Lower immunogenicity in these populations. These children may have a poor response to vaccines and therefore require additional doses. Markers such as CD4/CD8 or torque teno virus (TTV) replication could be linked to immunogenicity and thus serve as predictors of efficacy for routine clinical practice.

NCT ID: NCT05316064 Recruiting - Clinical trials for Human Papilloma Virus Infection

Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic

Start date: December 27, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of oral administration of probiotic at 9 log colony forming unit (CFU)/day to reduce vaginal abundance of HPV in women compared to placebo via the use of vaginal self-swab.

NCT ID: NCT01387997 Recruiting - Cervical Cancer Clinical Trials

e- Ab Sensor-based Real-time Detection of Oncogenic Human Papilloma Viruses

Start date: June 2010
Phase: N/A
Study type: Interventional

To develop a real-time diagnostic technique with e- Ab sensor for high risk human papilloma viruses(high risk HPV) detection, the investigators conduct a prospective clinical study. In comparison with results from direct sequencing of HPV, the investigators evaluate the performance of e- Ab sensor, including reproducibility, sensitivity, specificity, and cross-reaction (such as detection of low risk HPV). The potential factors which may interfere with the results would be investigated. With such a real-time diagnostic technique, the investigators hope to obtain information of patients in cost-saving and time-saving way and can give patients early treatment and offer more individualized treatment for our patients.